Status:
UNKNOWN
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
Lead Sponsor:
The University of Texas Health Science Center, Houston
Conditions:
HIV Infection
Eligibility:
FEMALE
18+ years
Brief Summary
Raltegravir is the first marketed strand-transfer inhibitor of HIV-1 that was FDA approved in 2007. It is currently one of the preferred treatment regimens for HIV by the Department of Health and Huma...
Eligibility Criteria
Inclusion
- HIV-infected women who picked up raltegravir in the year 2013 at Thomas Street Health Center.
- Minority women -Black/African American, Hispanic/Latino
Exclusion
- n/a
Key Trial Info
Start Date :
September 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2017
Estimated Enrollment :
254 Patients enrolled
Trial Details
Trial ID
NCT02302950
Start Date
September 1 2014
End Date
December 1 2017
Last Update
May 22 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thomas Street Clinic
Houston, Texas, United States, 77009